Table 3 Correlation between platelets–lymphocyte ratio and clinicopathological features
Parameters | Platelets–lymphocyte ratio | p value | |
|---|---|---|---|
Low (n = 74) | High (n = 44) | ||
Age at operation (years old) | |||
  ≤ 60 | 51 (68.9%) | 32 (72.7%) |  |
  > 60 | 23 (31.1%) | 12 (27.3%) | 0.661 |
Symptoms | |||
 Asymptomatic | 29 (39.2%) | 13 (29.5%) |  |
 Symptomatic | 45 (60.8%) | 31 (70.5%) | 0.290 |
Palpability | |||
 Impalpabe | 22 (29.7%) | 11 (25.0%) |  |
 Palpable | 52 (70.3%) | 33 (75.0%) | 0.580 |
Tumor size (mm) | |||
  ≤ 20.0 | 45 (60.8%) | 26 (59.1%) |  |
  > 20.0 | 29 (39.2%) | 18 (40.9%) | 0.854 |
Biopsy device | |||
 Core needle biopsy | 42 (56.8%) | 25 (56.8%) |  |
 Vacuum-assisted biopsy | 32 (43.2%) | 19 (43.2%) | 0.995 |
Estrogen receptor | |||
 Negative | 15 (20.3%) | 7 (15.9%) |  |
 Positive | 59 (79.7%) | 37 (84.1%) | 0.556 |
Progesterone receptor | |||
 Negative | 25 (33.8%) | 12 (27.3%) |  |
 Positive | 49 (66.2%) | 32 (72.7%) | 0.461 |
HER2 | |||
  ≤ 2 | 63 (82.4%) | 40 (90.9%) |  |
 3 | 13 (17.6%) | 4 (9.1%) | 0.205 |
Ki67 | |||
  ≤ 14% | 62 (83.8%) | 36 (81.8%) |  |
  > 14% | 12 (16.2%) | 8 (18.2%) | 0.783 |
Grade of DCIS | |||
 Low, intermediate | 60 (81.1%) | 38 (86.4%) |  |
 High | 14 (18.9%) | 6 (13.6%) | 0.460 |
Comedonecrosis | |||
 Absence | 36 (48.6%) | 18 (40.9%) |  |
 Presence | 38 (51.4%) | 26 (59.1%) | 0.666 |
Intraductal calcification | |||
 Absence | 63 (85.1%) | 36 (81.8%) |  |
 Presence | 11 (14.9%) | 8 (18.2%) | 0.635 |
Lymphoid infiltrate | |||
 Negative, mild | 49 (66.2%) | 34 (77.3%) |  |
 Moderate, severe | 25 (33.8%) | 10 (22.7%) | 0.204 |
LDH | |||
  ≤ ULN | 67 (90.5%) | 38 (86.4%) |  |
  > ULN | 7 (9.5%) | 6 (13.6%) | 0.484 |
CEA | |||
  ≤ ULN | 70 (94.6%) | 41 (93.2%) |  |
  > ULN | 4 (5.4%) | 3 (6.8%) | 0.753 |
CA15–3 | |||
  ≤ ULN | 71 (95.9%) | 44 (100.0%) |  |
  > ULN | 3 (4.1%) | 0 (0.0%) | 0.176 |
Postoperative pathology | |||
 DCIS only | 50 (67.6%) | 20 (45.5%) |  |
 Invasive ductal carcinoma | 24 (32.4%) | 24 (54.5%) | 0.018 |